GW0742
Metabolic / Fat LossAlso known as: GW-0742, GW 0742
Mechanism
GW0742 is a PPARdelta agonist structurally related to GW501516 (Cardarine) but with higher selectivity for PPARdelta over PPARalpha and PPARgamma. It is a research compound studied for its effects on fat metabolism, inflammation, and cardiovascular function. It has not entered clinical trials and its carcinogenicity profile is less characterized than GW501516.
Technical detail
GW0742 is a highly selective PPARδ agonist (EC50 ~1 nM for PPARδ vs ~1 μM for PPARα/γ, providing ~1000-fold selectivity). It activates similar fatty acid oxidation gene programs as GW501516 including upregulation of ABCA1, CPT1, and ADRP. Preclinical studies demonstrate anti-inflammatory effects via NF-κB suppression, improved lipid profiles, and enhanced fatty acid oxidation in cardiac and skeletal muscle. Long-term carcinogenicity data is limited compared to GW501516, making its safety profile uncertain.